<DOC>
	<DOCNO>NCT00375206</DOCNO>
	<brief_summary>The purpose study evaluate well vaccine tolerate site administration give effect may subject ' wellbeing . The study also test ability vaccine cause particular immune response body .</brief_summary>
	<brief_title>A Safety Immunology Study DNA Trivalent Influenza Vaccine</brief_title>
	<detailed_description>Influenza contagious disease upper airways lung . It rapidly spread around world seasonal epidemic , kill hundred thousand people high economic consequence due healthcare cost lose productivity . Each year government recommend group risk influenza complication receive influenza vaccination . Current vaccine supply sufficient meet demand recommendation take . This study part clinical development particle mediate epidermal delivery ( PMED ) trivalent DNA vaccine prevention influenza.This study investigate safety tolerability vaccine well assess humoral cellular immunogenicity vaccine healthy subject .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Ages Eligible Study : 18 Years 50 Years Genders Eligible Study : Both Accepts Healthy Volunteers Criteria Healthy adult volunteer ( woman must non childbearing potential ) Provided write informed consent No significant concomitant illness No allergy gold No immunosuppression due disease treatment No previous flu vaccination 2005 2006</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>PowderMed , DNA vaccine , influenza</keyword>
</DOC>